Focused On-demand Library for Protein archease

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IWT0

UPID:

ARCH_HUMAN

Alternative names:

Protein ZBTB8OS; Zinc finger and BTB domain-containing opposite strand protein 8

Alternative UPACC:

Q8IWT0; Q5TGK5; Q6PDA1; Q8IWS9; Q8NEV6; Q8NEV7

Background:

Protein archease, also known as Protein ZBTB8OS and Zinc finger and BTB domain-containing opposite strand protein 8, plays a crucial role in the tRNA-splicing ligase complex. It is essential for the enzymatic turnover of catalytic subunit RTCB, working alongside DDX1 to facilitate RTCB's guanylylation, a pivotal step in tRNA ligation.

Therapeutic significance:

Understanding the role of Protein archease could open doors to potential therapeutic strategies. Its involvement in the fundamental process of tRNA ligation highlights its importance in cellular biology and presents an opportunity for targeted drug discovery.